Is There A 2nd-Generation Venetoclax in the Pipeline?

[DRM18]

Hi folks,

Title about says it all. Just curious!

—Dave!

[SofiaDeo]

yes, there are at least these:

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/resu...

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

There's more I am sure.

[DRM18 in reply to SofiaDeo]

Thank you, SofiaDeo; I bow down to you, madam!

—Dave!

[Sushibruno in reply to DRM18]

I hope you're well DMR18.

[DRM18 in reply to Sushibruno]

Thank you, Sushibruno! You too!

[Sushibruno in reply to DRM18]

im heading to Dr. Lamannas office. IM SO anxious.

[Sushibruno in reply to SofiaDeo]

wow i had no idea👍👍

[spi3 in reply to SofiaDeo]

there doesn't appear any test results posted...

[SofiaDeo in reply to spi3]

Clinical trials may not post results until a trial is completed. So these and others are "in the pipeline" but we may only get major press when something is near submission for FDA or other country approval. If there is enough data, and interim results are promising, sometimes a poster at a medical conference, or a Letter to the Editor or other interim publication may be submitted to a journal. Or a drug company may put out a Press Release. But I am not aware of publications/publishing of "trials that looked promising but petered out" other than the hoopla surrounding hydroxychloroquine and ivermectin for treating Covid-19. That was more unusual, as opposed to the norm. Outside of specialized research circles, there isn't much published (in the mainstream media anyway) about newer ongoing research, or things that looked good but failed.

[spi3 in reply to SofiaDeo]

Ty so much for this information - there is so much new immunotherapys out there it gives me such hope that one day there will be a cure for EVERY one with leukemia and any type of cancers

[CLLerinOz Administrator]

One novel BCL2 inhibitor being trialled is BGB-11417. Ann Liu from the CLL Society wrote about it earlier this year. Her article includes a summary of key information about BGB-11417 and an interview with Prof Con Tam who discusses the preliminary results from an ongoing phase 1 clinical trial studying its safety and efficacy alone and in combination with the next-generation BTK inhibitor zanubrutinib.

cllsociety.org/2022/04/ash-...

The results were presented at last year's ASH 2021 conference.

beigenemedical.com/Congress...

[AussieNeil Partner Administrator in reply to CLLerinOz]

In addition to BeiGene's BGB -11417 mentioned by CLLerinOz , we have the following BCL-2 inhibitors:-

- Bio-Path's BP1002

- Lupeng's LP-108

- Lisaftoclax's APG-2575

- Loxo Oncology's LOXO-338

See: healthunlocked.com/cllsuppo...

Neil

[Big_Dee in reply to AussieNeil]

Hello AussieNeil

Things are looking up.

[Schubert1870 in reply to AussieNeil]

To think just a few years ago Imbruvica was the star, and since then there all these new up and coming drugs. My head is spinning! 🙃 What a blessing it is to be living at this time of life.

[fugazi in reply to Schubert1870]

Good call.

As someone about to need a second line of treatment, I'm chuffed at the options that have become available since I was diagnosed.

There's alot going wrong in the world, but also a hell of alot going right, and research and breakthroughs in medicine are to be applauded loudly.

[spi3 in reply to CLLerinOz]

thank you

[hope-73]

I suppose the next question would: do any of these look like they could be as good as or even better than Venetoclax?

[Jmiah717 in reply to hope-73]

I saw one that was safer and looked at least as effective. I cant remember the name though.

[bennevisplace]

I'm glad you asked, the question had wafted by me more than once.

Does anyone know the price of Ven in the US?

In the UK Ven was licensed Oct 2018 when... The listed cost of a course is £4,789, but the NHS has been offered an undisclosed discount by the manufacturer Abbvie b-s-h.org.uk/about-us/news/...

[DRM18 in reply to bennevisplace]

Hi bennevisplace,

Without insurance, the price is absurd, like 15000$ a month.

But if you have private insurance, the drug company will pay the co-pay (as long as the private insurance is paying them ;-), leaving the patient with a 5$-a-month charge.

Don't know anything about Medicare/Medicaid/etc.

--Dave!

[bennevisplace in reply to DRM18]

Thanks. $15k a month sounds a lot, but I find £5k for a course (what does that even mean? 6/ 12 mths?) absurdly cheap, which is why I asked. I guess the insurance company would pay much less than $15k.

[DanBro1 in reply to bennevisplace]

Bennevisplace, are you sitting down???? These are 100% accurate numbers from my own financial records: Venclexta cost me 5% out of pocket copay of $653.69 monthly. Medicare paid an additional $12,456.00 for a total of $13,080 per month for 12 months. (Venclexta list price is $16,185 per month). I had six once per month infusions of Obinutuzumab (Gazyva) at a cost of $42, 204 per infusion. An infusion nurse told me this price as I did not receive a bill because it as done in a hospital setting. Total cost of Gazyva treatment 6 x $42,204 = $253,224. Total cost of Venclexta tablets ($156,960). As a sidenote, I also buy a drug called Farxiga 10 mg from Canada. It costs me $145 for 90 day supply plus $12 shipping. Here is my Medicare Humana Part D price for this same drug 90 day supply, showing my copay and what Humana pays and total price. We wonder why Medicare is going broke??

Farxiga Medicare Part D Humana 90 Day Price

[bennevisplace in reply to DanBro1]

Thank you, at those prices it's hard to see this as a balanced healthcare system, easy to see why the US per capita average is so high.

The Farxiga example.. how can such a price difference be?

[DanBro1 in reply to bennevisplace]

How can there be such a price difference, you ask?? Easy answer. Big Pharma owns the US congress. US pharma prices use the Harvard Business School formula for setting prices, i.e., "whatever the market will bear". Canada, UK, France, etc. make the pharma companies submit prices with a fair profit only. Most industries, if you earn 10%-15% net profit, that is considered a nice return. Big Pharma in the US earns triple that amount. Remember that Net Profit is gross profit minus operating expenses and taxes. It is basically total income minus all expenses. After paying for corporate offices, salaries, bonuses, corporate jets, etc. Venclexta (AbbVie) CEO makes almost $25 Million dollars per year salary/bonus, for example.

[SofiaDeo in reply to DanBro1]

And they get a nice tax deduction for giving away such "high priced meds" to those who qualify. Which often means the patient has to have enough money/knowledge to be able to see a patient website, etc. with numbers to call/places to email. My neighbor with CLL has no computer, or email, recently got his first smartphone ever, and his non specialist hem-onc is unaware of the patient resources available for zanubrutinib and other meds like venetoclax. The drugs reps aren't marketing their free drug services here in the US, just the drugs.

[jonathan7176]

Is venetoclax considered a potential second line of treatment for those who've previously been on the 'brutinibs?

[joanne17 in reply to jonathan7176]

I was on Ibrutinib for6 years when it stopped working my Medical team has me signed up for Venetoclax .Should begin in another week.

[jonathan7176 in reply to joanne17]

Bon chance Joanne.

[Fastbike14 in reply to joanne17]

I'm starting my 5th week titraton of Venetoclax. Little or no side effects and feeling better than i have for ages. Hope it works out the same way for you

[bayside64]

LOXO 338 combined with Venetoclax is being studied right now and hopefully will be the next miracle combo especially people sensitive to all the "brutinibs."